Beaufort Securities Reaffirms Speculative Buy Rating for Tiziana Life Sciences PLC (TILS)
Tiziana Life Sciences PLC (LON:TILS)‘s stock had its “speculative buy” rating restated by equities researchers at Beaufort Securities in a research report issued on Friday.
Shares of Tiziana Life Sciences PLC (LON:TILS) opened at 190.00 on Friday. The company’s market cap is GBX 175.54 million. Tiziana Life Sciences PLC has a 1-year low of GBX 91.35 and a 1-year high of GBX 232.95. The company has a 50-day moving average of GBX 190.67 and a 200-day moving average of GBX 158.52.
About Tiziana Life Sciences PLC
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. The Company is engaged in the research and development of biotechnological and pharmaceutical products. Its subsidiary, Tiziana Pharma Limited (TPL), is formed as a vehicle to acquire and exploit certain intellectual property in biotechnology, specifically a program focused on metastatic breast cancer.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.